Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)
Study sponsor: Fulcrum Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-01-28Actual
Enrollment · participants80Actual
Source updated2024-07-10Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.